Akebia Therapeutics (AKBA) Consolidated Net Income: 2016-2025
Historic Consolidated Net Income for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to $540,000.
- Akebia Therapeutics' Consolidated Net Income rose 102.69% to $540,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 65.42%. This contributed to the annual value of -$69.4 million for FY2024, which is 33.67% down from last year.
- Per Akebia Therapeutics' latest filing, its Consolidated Net Income stood at $540,000 for Q3 2025, which was up 118.62% from $247,000 recorded in Q2 2025.
- Over the past 5 years, Akebia Therapeutics' Consolidated Net Income peaked at $29.0 million during Q2 2022, and registered a low of -$84.3 million during Q2 2021.
- For the 3-year period, Akebia Therapeutics' Consolidated Net Income averaged around -$10.4 million, with its median value being -$11.2 million (2023).
- As far as peak fluctuations go, Akebia Therapeutics' Consolidated Net Income skyrocketed by 134.44% in 2022, and later tumbled by 3,814.01% in 2024.
- Quarterly analysis of 5 years shows Akebia Therapeutics' Consolidated Net Income stood at -$70.4 million in 2021, then surged by 90.76% to -$6.5 million in 2022, then soared by 109.44% to $614,000 in 2023, then slumped by 3,814.01% to -$22.8 million in 2024, then spiked by 102.69% to $540,000 in 2025.
- Its Consolidated Net Income stands at $540,000 for Q3 2025, versus $247,000 for Q2 2025 and $6.1 million for Q1 2025.